Skip to content
Screener

Rapport Therapeutics, Inc. RAPP Free cash flow margin

Free cash flow margin at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
23.3%-7.3pp
Supernus Pharmaceuticals logo
Supernus PharmaceuticalsSUPN
27.9%+3.4pp
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
-3,732.2%—
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
-3,067.4%-1,030pp
Septerna, Inc. logo
Septerna, Inc.SEPN
467.9%+243pp
Neuropace, Inc. logo
Neuropace, Inc.NPCE
-10.3%-3.5pp

Other financials

Income statement

See full
Revenue-—
Operating income-$60.8M-106%
Net income-$56.6M-112%
EPS (diluted)-$1.19-58.7%

Balance sheet

See full
Cash & equivalents$63.6M+15.5%
Total debt$10.1M-14.8%
Total equity$422.9M+60.5%
Total assets$459.0M+60.8%

Cash flow

See full
Operating cash flow-$41.5M-65.4%
CapEx$78.0K+255%
Free cash flow-$41.5M-65.5%

Valuation

See full
Market cap$2.22B+317%
Enterprise value$2.17B+343%
P/S111.2×—

Profitability

See full
Operating margin-767.6%—
Net margin-685.8%—

Returns & leverage

See full
Return on equity-40%+22.3pp
Debt / equity0×0.0×
Current ratio15.7×-7.0×